Irem akın şen

Dr. Irem akın şen

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2021 in Balkan Medical Journal
Verified
Journal Article
Open access
KGKursat Gundogan
Kursat Gundogan
İAİsmail Hakkı Akbudak
İsmail Hakkı Akbudak
PHPervin Hancı
Pervin Hancı
BHBurcin Halaci
Burcin Halaci
STSahin Temel
Sahin Temel
ATArzu Topeli
Arzu Topeli
There are limited data on the long-term outcomes of COVID-19 from different parts of the world. To determine risk factors of 90-day mortality in critically ill patients in Turkish intensive care units (ICUs), with respiratory failure. Retrospective, observational cohort. Patients with laboratory-confirmed COVID-19 and who had been followed up in the ICUs with respiratory failure for more than 24 hours were included in the study. Their demographics, clinical characteristics, laboratory variables, treatment protocols, and survival data were recorded. A total of 421 patients were included. The median age was 67 (IQR: 57-76) years, and 251 patients (59.6%) were men. The 90-day mortality rate was 55.1%. The factors independently associated with 90-day mortality were invasive mechanical ventilation (IMV) (HR 4.09 [95% CI: [2.20-7.63], P < .001), lactate level >2 mmol/L (2.78 [1.93-4.01], P < .001), age ≥60 years (2.45 [1.48-4.06)], P < .001), cardiac arrhythmia during ICU stay (2.01 [1.27-3.20], P = .003), vasopressor treatment (1.94 [1.32-2.84], P = .001), positive fluid balance of ≥600 mL/day (1.68 [1.21-2.34], P = .002), PaO2/FiO2 ratio of ≤150 mmHg (1.66 [1.18-2.32], P = .003), and ECOG score ≥1 (1.42 [1.00-2.02], P = .050). Long-term mortality was high in critically ill patients with COVID-19 hospitalized in intensive care units in Turkey. Invasive mechanical ventilation, lactate level, age, cardiac arrhythmia, vasopressor therapy, positive fluid balance, severe hypoxemia and ECOG score were the independent risk factors for 90-day mortality.

20 October 2023 in Balkan Medical Journal
Verified
Journal Article
Open access
FGFethi Gül
Fethi Gül
UKUmut Sabri Kasapoglu
Umut Sabri Kasapoglu
MSMehmet Süleyman Sabaz
Mehmet Süleyman Sabaz
PAPınar Ay
Pınar Ay
BOBurçin Doruk Oktay
Burçin Doruk Oktay
SASeda Banu Akıncı
Seda Banu Akıncı
Background: Vaccines against coronavirus disease-19 (COVID-19) have been effective in preventing symptomatic diseases, hospitalizations, and intensive care unit (ICU) admissions. However, data regarding the effectiveness of COVID-19 vaccines in reducing mortality among critically ill patients with COVID-19 remains unclear.Aims: To determine the vaccination status and investigate the impact of the COVID-19 vaccine on the 28-day mortality in critically ill patients with COVID-19.Study Design: Multicenter prospective observational clinical study.Methods: This study was conducted in 60 hospitals with ICUs managing critically ill patients with COVID-19. Patients aged >= 18 years with confirmed COVID-19 who were admitted to the ICU were included. The present study had two phases. The first phase was designed as a one-day point prevalence study, and demographic and clinical findings were evaluated. In the second phase, the 28-day mortality was evaluated.Results: As of August 11, 2021, 921 patients were enrolled in the study. The mean age of the patients was 65.42 +/- 16.74 years, and 48.6% (n = 448) were female. Among the critically ill patients with COVID-19, 52.6% (n = 484) were unvaccinated, 7.7% (n = 71) were incompletely vaccinated, and 39.8% (n = 366) were fully vaccinated. A subgroup analysis of 817 patients who were unvaccinated (n = 484) or who had received two doses of the CoronaVac vaccine (n = 333) was performed. The 28-day mortality rate was 56.8% (n = 275) and 57.4% (n = 191) in the unvaccinated and two-dose CoronaVac groups, respectively. The 28-day mortality was associated with age, hypertension, the number of comorbidities, type of respiratory support, and APACHE II and sequential organ failure assessment scores (p < 0.05). The odds ratio for the 28-day mortality among those who had received two doses of CoronaVac was 0.591 (95% confidence interval: 0.413-0.848) (p = 0.004).Conclusion: Vaccination with at least two doses of CoronaVac within six months significantly decreased mortality in vaccinated patients than in unvaccinated patients.

17 October 2025 in Medicine
Verified
Journal Article
Open access
IŞIrem akın şen
Irem akın şen
This study aimed to investigate the prognostic value of admission serum magnesium levels and systemic inflammatory indices, including C-reactive protein (CRP), neutrophil-to-lymphocyte ratio, systemic immune-inflammation index (SII), and multiple inflammation index, for predicting key clinical outcomes in critically ill patients with sepsis aged ≥ 85 years. This retrospective observational study was conducted to evaluate the prognostic value of admission serum magnesium and systemic inflammatory indices in critically ill patients with sepsis aged ≥ 85 years. Patients were stratified by serum magnesium levels into hypomagnesemia (2.4 mg/d). The prognostic performance for intensive care unit (ICU) mortality, 28-day mortality, mechanical ventilation requirement, and prolonged ICU stay was assessed using receiver operating characteristic curve analysis and multivariable Cox proportional hazards models. Among 381 patients aged ≥ 85 years (mean age 89.2 ± 3.2; 59.3% male) admitted to the ICU with sepsis, the ICU and 28-day mortality rates were 33.1% and 37.8%, respectively. Hypermagnesemia (>2.4 mg/dL) was observed in 18.9% of patients and was associated with higher sequential organ failure assessment (sequential organ failure assessment) scores (9.2 ± 3.1), CRP (129.7 ± 84.6 mg/L), neutrophil-to-lymphocyte ratio (15.2 ± 10.8), and multiple inflammation index (564.3 × 10³), with an ICU mortality of 52.8% ( P = .001) and 28-day mortality of 61.1% ( P < .001). In ICU patients with sepsis aged ≥ 85 years, hypermagnesemia at admission was a strong and independent predictor of mortality.

30 May 2022 in European Journal of Inflammation
Verified
Journal Article
Open access
IŞIrem akın şen
Irem akın şen
ÖKÖmer Karaşahin
Ömer Karaşahin
EŞEngin Şebin
Engin Şebin
CŞCem Şen
Cem Şen
Objective: Considering the published manuscripts on this subject, it is thought that IL-1B and azurocidin may be diagnostic and prognostic factors in severe COVID-19 disease. This study aimed to determine whether azurocidin and IL-1β are useful biomarkers and are associated with disease exacerbation in patients needing advanced treatment options. Material and Method: Our study was performed retrospectively. The data of a total of 291 patients followed in the hospital due to COVID-19 were collected. Among these patients, 66 randomly selected patients were included in this study. The control group consisted of 24 healthy individuals referred to the infectious disease outpatient clinic who weren’t no diagnosis of COVID-19 infection or any other infection. After the samples were taken into tubes without anticoagulant, they were kept at room temperature for 30 min. Afterwards, it was centrifuged at 1000xg for 15 min at +4° according to the instructions of the ELISA kit we used. The remaining serum was transferred to Eppendorf tubes and stored at −80° throughout this study. Results: A statistically significant strong positive correlation was determined between IL1β and azurocidin. A statistically significant weak positive correlation was found between IL1β and CRP, ferritin and neutrophil count, weak negative correlation with albumin, and moderately strong positive correlation with leukocyte count. Moreover, a statistically significant weak positive correlation was found between azurucidin and CRP, ferritin, and neutrophil counts. Conclusion: Azurocidin and IL-1β may serve as a potential therapeutic target for patients at risk of developing systemic multi-organ failure, with improved patient prognosis and prevention of death in severely ill patients. Although these results may contribute to the improvement of the follow-up and treatment of the patients and reduce mortality rates, there is a need for randomized controlled studies with a larger number of patients to be performed in the future.

3 January 2023 in Jundishapur Journal of Microbiology
Verified
Journal Article
Open access
PDF file
EKEmine Fusun Karasahin
Emine Fusun Karasahin
ESEngin Sebin
Engin Sebin
IŞIrem akın şen
Irem akın şen
OKOmer Karasahin
Omer Karasahin
Background: SARS-CoV-2 infections (COVID-19) first occurred in Wuhan, China, in December 2019 and spread worldwide, causing significant mortality and morbidity. IL-17A may mediate numerous immunopathological effects secondary to cytokine release syndrome during SARS-CoV-2 infection. However, there has not been enough research on its effect on prognosis. Objectives: This study evaluated the predictive power of serum interleukin (IL)-17A level as a prognostic marker in COVID-19. Methods: The study included 152 patients diagnosed with COVID-19 by real-time polymerase chain reaction analysis of nasopharyngeal swab samples in the infectious diseases department and intensive care unit of our hospital between October 1 and December 31, 2020. The control group consisted of 40 asymptomatic healthcare workers who had negative RT-PCR results during routine COVID-19 screening in our hospital. Samples were collected in anticoagulant-free tubes and left at room temperature for 30 minutes. Afterward, it was centrifuged at 1000 × g for 15 minutes at 4°C per the instructions provided with the enzyme-linked immunoassay (ELISA) kit. Serum IL-17A levels were measured using the Human Interleukin 17A ELISA Kit. Results: Serum IL-17A levels were significantly higher in COVID-19 patients than in controls (P < 0.001). IL-17A levels increased significantly in association with disease severity in patients with the moderate, severe, and critical disease, with a less pronounced difference between severe and critical patients (moderate vs. severe, P < 0.001; severe vs. critical, P = 0.048). IL-17A levels at hospital admission and day 7 were significantly higher in non-surviving patients (P < 0.001). At a cut-off value of 210.25 ng/L, IL-17A at admission had a predictive power of 0.792 (P < 0.001). Compared to baseline, IL-17A values on day seven were significantly increased in non-survivors (P = 0.004) and decreased in survivors (P = 0.014). An increase of 26.17 ng/L or more on day 7 had a predictive mortality power of 0.634 (P = 0.005). Conclusions: The results of this study suggest that IL-17A, an important part of the immune system previously shown to be useful in the treatment and follow-up of COVID-19, may also help predict mortality in COVID-19 patients.

20 November 2023 in Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi
Verified
Journal Article
Closed access
IŞIrem akın şen
Irem akın şen
ŞAŞenol Arslan
Şenol Arslan
CŞCem Şen
Cem Şen
Giriş: Dünya Sağlık Örgütü (DSÖ) tarafından Aralık 2019 yılında pandemi ilan edilen COVİD-19 salgını sonrası, Mart’ın ikinci haftasından itibaren ülkemizde olgular bildirilmiştir. COVİD-19 olgularının %5’inde hastalığın seyri sırasında yoğun bakım ünitesine (YBÜ) yatış ihtiyacı gelişmektedir.Bu çalışma ile YBÜ’de izlediğimiz kritik durumdaki COVİD-19 hastalarından sürekli renal replasman(CRRT) tedavisi ihtiyacı olan hastaların mortalite oranlarını APACHE-II ve SOFA skoru ile değerlendirmesi amaçlanmıştır. Gereç ve Yöntem: Mart –Eylül 2020 arasında Eğitim Araştırma Hastanesinin Anestezi Yoğun Bakım Ünitesine yatırılıp CRRT ihtiyacı olan 13 hasta APACHE-II ve SOFA skorlama sistemi ile değerlendirildi.CRRT uygulamasından önce ve uygulamadan 2 gün sonra APACHE-II ve SOFA skorları kayıt edildi. Mortalite açısından skorlama sistemileri kıyaslandı. Bulgular: CRRT öncesi ve sonrası APACHE-II ve SOFA skorlama sitemleriine bakıldığında; CRRT öncesi APACHE-II skorlama sisteminin tahmini ölüm oranın öngörmede daha belirleyici olduğu; fakat CRRT sonrası APACHE-II ve SOFA skorlama sisteminin birbiriyle farkı olmadığı görülmüştür.Hastanede yatış süreleri değerlendirildiğinde;APACHE-II ile SOFA skorlama sistemi arasında negatif yönde bir ilişki bulunmuştur. Sonuç: Çalışmamız literatür ile uyumlu olarak erkeklerde ve hipertansiyonu olan hastalarda mortalitenin daha yüksek olduğunu göstermiştir. APACHE-II ve SOFA skoru arasında CRRT sonrasında mortalite açısından fark olmadığını her iki sisteminde kullanılabileceğini göstermektedir. Bu sonuçların gelecekteki takip ve tedavi yöntemlerine katkı sağlayabileceği düşünülmekle birlikte yeni çalışmalara ihtiyaç vardır.